Search - tctmd.com

Displaying 21 - 40 of 334

Sort: Relevancy | Date

Presentation TCT 2023

TCT 165: Aspirin-Free Prasugrel Monotherapy: Thirty Days Clinical Outcome after Percutaneous Coronary Intervention in Chronic Coronary Syndrome and Non-ST Segment Elevation Acute Coronary Syndrome

Presenter: Gaku Nakazawa

October 26, 2023

Presentation TCT 2023

TCT 706: 3-6 Month vs 12 Month Dual Antiplatelet Therapy After Drug Eluting Stent Placement: An Updated Meta-Analysis

Presenter: Aakash Garg

October 25, 2023

Presentation TCT 2023

TCT 659: De-escalation of antiplatelet therapy in elderly or low-weight patients with myocardial infarction.

Presenter: Hyunki LEE

October 25, 2023

Presentation TCT 2023

TCT 381: The Clinical implementation of CYP2C19 genotyping in patients with an acute coronary syndrome: Insights from the FORCE-ACS registry

Presenter: Jaouad Azzahhafi

October 25, 2023

Presentation TCT 2023

TCT 135: Ticagrelor Coated Stent to Eliminate the Need for DAPT post-PCI

Presenter: Jared Romeo

October 25, 2023

Presentation TCT 2023

TCT 99: Efficacy and safety of early single direct oral anticoagulant therapy within one year after coronary stent implantation in patients with atrial fibrillation

Presenter: Taehoon Kim

October 25, 2023

Presentation TCT 2023

TCT 11: Clinical impact of dyspnea after ticagrelor treatment and the effect of switching to clopidogrel in patients with myocardial infarction

Presenter: Sang Hyun Kim

October 25, 2023

Presentation TCT 2023

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

Presenter: Hyunki LEE

October 25, 2023

Presentation TCT 2023

TCT 525: The Prevalence of Bleeding and Ischemic Outcomes in Patients on Triple Therapy in a Real-Practice Registry of Percutaneous Coronary Interventions

Presenter: Eva Woelders

October 25, 2023

Presentation TCT 2023

TCT 507: Association of CYP2C19*17 Carrier Status to Ischemic and Bleeding Outcomes Among Patients with Coronary Artery Disease Treated with Clopidogrel: a Meta-Analysis

Presenter: Cole Clifford

October 25, 2023

Presentation TCT 2023

TCT 380: The impact of obesity on antiplatelet monotherapy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial

Presenter: Minju Han

October 25, 2023

Presentation TCT 2023

TCT 42: Does Heparin-induced thrombocytopenia affect in-hospital outcomes in patients presenting with ST-segment elevation myocardial infarction? A nationwide data analysis.

Presenter: Purveshkumar Patel

October 25, 2023

Presentation TCT 2023

TCT 457: Impact of Uninterrupted Versus Interrupted Oral Anticoagulation on 30-Day Outcomes in Patients Undergoing Coronary Angiography

Presenter: Ting-Yu Wang

October 25, 2023

Presentation TCT 2023

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

Presenter: Pieter Smits

October 25, 2023

Presentation TCT 2023

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

Presenter: Seong Huan Choi

October 25, 2023

Presentation TCT 2023

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

Presenter: Ji-Yeon Kim

October 25, 2023

Presentation TCT 2023

TCT 30: Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

Presenter: Byeong-Keuk Kim

October 25, 2023

Presentation TCT 2023

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

Presenter: John Bittl

October 25, 2023

Presentation TCT 2023

Longer Term DAPT Is What The Guidelines and Data Support

Presenter: Mamas Mamas

October 25, 2023

Presentation TCT 2023

DAPT After PCI: Do We Need It at All?

Presenter: Fausto Feres

October 24, 2023

Advertisement

TCT 165: Aspirin-Free Prasugrel Monotherapy: Thirty Days Clinical Outcome after Percutaneous Coronary Intervention in Chronic Coronary Syndrome and Non-ST Segment Elevation Acute Coronary Syndrome

TCT 706: 3-6 Month vs 12 Month Dual Antiplatelet Therapy After Drug Eluting Stent Placement: An Updated Meta-Analysis

TCT 659: De-escalation of antiplatelet therapy in elderly or low-weight patients with myocardial infarction.

TCT 381: The Clinical implementation of CYP2C19 genotyping in patients with an acute coronary syndrome: Insights from the FORCE-ACS registry

TCT 135: Ticagrelor Coated Stent to Eliminate the Need for DAPT post-PCI

TCT 99: Efficacy and safety of early single direct oral anticoagulant therapy within one year after coronary stent implantation in patients with atrial fibrillation

TCT 11: Clinical impact of dyspnea after ticagrelor treatment and the effect of switching to clopidogrel in patients with myocardial infarction

TCT 657: Aspirin versus P2Y12 inhibitor as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation (AF).

TCT 525: The Prevalence of Bleeding and Ischemic Outcomes in Patients on Triple Therapy in a Real-Practice Registry of Percutaneous Coronary Interventions

TCT 507: Association of CYP2C19*17 Carrier Status to Ischemic and Bleeding Outcomes Among Patients with Coronary Artery Disease Treated with Clopidogrel: a Meta-Analysis

TCT 380: The impact of obesity on antiplatelet monotherapy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial

TCT 42: Does Heparin-induced thrombocytopenia affect in-hospital outcomes in patients presenting with ST-segment elevation myocardial infarction? A nationwide data analysis.

TCT 457: Impact of Uninterrupted Versus Interrupted Oral Anticoagulation on 30-Day Outcomes in Patients Undergoing Coronary Angiography

The Primary Endpoint Results from the COMPARE 60/80 HBR Trial: A Randomized Controlled Multi-Center Trial Comparing Ultrathin With Thin Strut Stents in High Bleeding Risk Patients With an Abbreviated DAPT Duration

TCT 354: The clinical impact of Dual Antiplatelet Therapy score combined with P2Y12 reactivity unit on East Asian patients who received drug eluting stent implantation; PTRG-DES Consortium

TCT 37: The association of CHADS-P2A2RC risk score with clinical outcomes in patients taking P2Y12 inhibitor monotherapy after 3 months of dual antiplatelet therapy following percutaneous coronary intervention

TCT 30: Predicting Individual Treatment Effects to Determine Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation

The Guidelines Need Updating: 3-6 Months of DAPT Is Sufficient

Longer Term DAPT Is What The Guidelines and Data Support

DAPT After PCI: Do We Need It at All?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content